Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
14 Results for "
ADP-Glo
" in MedChemExpress (MCE) Product Catalog:
Products (14)
14 Results for "ADP-Glo" in MCE Product Catalog:
2
2 Cited Publications
Target:
Research Areas:
NDI-091143 is a potent and high-affinity human ATP-citrate lyase (ACLY) inhibitor with an IC50 of 2.1 nM (ADP-Glo assay), a Ki of 7.0 nM and a Kd of 2.2 nM. NDI-091143 inhibits ACLY catalysis allosterically, by stabilizing large conformational changes in the citrate domain that indirectly block the binding and recognition of citrate .
SBP-7455 is a potent, high affinity and orally active dual ULK1/ULK2 autophagy inhibitor with IC50s of 13 nM and 476 nM in the ADP-Glo assays, respectively. SBP-7455 potently inhibits ULK1/2 enzymatic activity and can be used for triple-negative breast cancer (TNBC) research .
Synonyms: PF-367
Target:
Research Areas:
PF-04802367 (PF-367) is a highly selective GSK-3 inhibitor with an IC50 of 2.1 nM based on a recombinant human GSK-3β enzyme assay and 1.1 nM based on ADP-Glo assay. PF-04802367 shows desirable central nervous system (CNS) properties and potency. PF-04802367 is equally effective at inhibition of the two known GSK-3 isoforms (GSK-3α and GSK-3β) with IC50 values of 10.0 and 9.0 nM in mobility shift assays, respectively .
Cat. No.: HY-18901
CAS No.: 1481641-08-0
Target:
Research Areas:
RIPK1-IN-4 (compound 8) is a potent and selective type II kinase inhibitor of receptor interacting protein 1 (RIP1) kinase and binds to a DLG-out inactive form of RIP1 with an IC50s of 16 nM and 10 nM for RIP1 and ADP-Glo kinase .
Cat. No.: HY-151350
CAS No.: 2927429-64-7
Target:
Research Areas:
SphK2-IN-1 is a SphK2 inhibitor (IC50: 0.359 μM). SphK2-IN-1 can be used in the research of cancer, inflammation, neurological and cardiovascular disorders .
Cat. No.: HY-161570
CAS No.: 3032733-05-1
Target:
Research Areas:
LRRK2-IN-12 (compound 1) inhibits the activity of LRRK2 G20195 (IC50=0.45 nM), LRRK2 WT (IC50=1.1 nM) and LRRK2 WT ADP-Glo (IC50=0.46 nM). LRRK2-IN-12 can be used for Alzheimer's Disease research .
Cat. No.: HY-178150
CAS No.: 2803921-87-9
WEE1-IN-14 (Compound 14) is a selective WEE1 inhibitor (IC50: 0.5 nM in L-RB-FEP calculations, 1.0 nM in ADP-Glo kinase assay). Inhibition of Wee1 in cancer cells disrupts the G2-M checkpoint, removes the regulatory controls on the cell cycle, and leads to early onset of mitotic failure followed by apoptosis of tumor cells. Therefore, WEE1-IN-14 is a useful tool for studying cancer biology .
Cat. No.: HY-168024
Target:
Research Areas:
NOD1/2-IN-1 (Compound 18) is a potent RIPK2 inhibitor with an IC50 value of 1.4 nM, as determined by the ADP-Glo assay. NOD1/2-IN-1 blocks the production of pro-inflammatory cytokines by inhibiting the NOD1/NOD2 pathways, with IC50 values of 18 nM and 170 nM for NOD1 and NOD2, respectively, thereby reducing inflammatory responses. NOD1/2-IN-1 can be used in studies related to colitis .
Cat. No.: HY-162237
Target:
Research Areas:
RIPK1-IN-13 (compound 28) is a selective inhibitor for receptor-interacting serine/threonine-protein kinase 1 (RIPK1), the inhibitory activity is measured by ADP-Glo Kinase Assay with a pKi of 7.66. RIPK1-IN-13 inhibits human leukaemia cells U937 with a pIC50 of 7.2 .
Cat. No.: HY-168023
CAS No.: 687627-78-7
Target:
Research Areas:
NOD1/-IN-1 (Compound 2) is a potent RIPK2 inhibitor with an IC50 value of 0.65 nM determined by ADP-Glo assays. NOD1/-IN-1 selectively inhibits the NOD1 pathway (with an IC50 of 33 nM for NOD1), blocking the production of pro-inflammatory cytokines and thereby reducing inflammation. NOD1/-IN-1 is applicable for research in the field of colitis .
Cat. No.: HY-155865
CAS No.: 2902671-74-1
CCT368772 (compound 35) is a selective kinesin HSET inhibitor (HSET ADP-Glo IC50 = 0.019 μM). CCT368772 exhibits selectivity over Eg5 (Eg5 ADP-Glo IC50 >200 μM) . CCT368772 (compound 152) can be used for the study of hyperproliferative diseases and disorders such as cancer .
Cat. No.: HY-184427
Target:
Research Areas:
WRN-IN-27 is a potent, selective and orally active Werner syndrome RecQ helicase (WRN) inhibitor. WRN-IN-27 inhibits WRN with IC50 values of 20.0 nM and 43.2 nM in the ADP-Glo kinase assay and fluorometric helicase assay, respectively. WRN-IN-27 inhibits MSI-H cell growth selectively (GI50 = 61.8-440 nM), and exhibits antitumor activity in the colon cancer model for MSI-H tumor research .
Cat. No.: HY-181004
PKMYT1-IN-13 is a potent, orally active and selective PKMYT1 inhibitor that inhibits PKMYT1 with IC50 values < 10.0 nM in ADP-Glo assay and 19.9 nM in NanoBRET cellular assay. PKMYT1-IN-13 exhibits high selectivity over WEE1. PKMYT1-IN-13 shows selective antiproliferative activity in CCNE1-amplified cells, while showing minimal wild-type effects. PKMYT1-IN-13 shows antitumor efficacy in HCC1569 mouse xenografts. PKMYT1-IN-13 can be used for the research of CCNE1-amplified cancers, such as gastric, ovarian, and breast cancer .
Cat. No.: HY-183672
Target:
Research Areas:
c-Met-IN-28 is a type III allosteric inhibitor of c-MET, with pKi values of 7.4 (WT) and 7.1 (D1228V), and IC50 values of 37 nM (WT) and 72 nM (D1228V) against human c-MET. c-Met-IN-28 can be used for research on c-MET-driven cancers .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
